Targacept commences TC-5619 Phase 2 study of cognitive dysfunction in schizophrenia (News-Medical-Net)
Posted by
in
Recent Domain News on
December 10th, 2009 |
no responses
Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia.
Read the rest here:
Targacept commences TC-5619 Phase 2 study of cognitive dysfunction in schizophrenia (News-Medical-Net)
